Roll Call: Latest News on Capitol Hill, Congress, Politics and Elections
August 5, 2015

Congressional Stock Transactions — Warner Is Buying, Issa Is Counting

Recent stock transactions by members of Congress show some Senators are in a buying mood. Stock transactions of members are required to be disclosed under the Stop Trading on Congressional Knowledge (STOCK) Act.

Sen. Mark Warner, D-Va., has reported buying $500,001 to $1 million worth of Novus Special Situations LLC on July 18. He also bought $250,001 to $500,00 worth of Norwegian Crystals AS on July 26.

Sen. John Hoeven, R-N.D., reported he bought $100,001 to $250,000 of Westbrand Inc. Bank Holding Company, Minot, N.D., on July 26.

In reports required under the Ethics in Government Act, U.S. senatorial candidate and Newark Mayor Cory Booker amended his personal financial disclosure report to add an additional source of income. He reported he received $37,500 from Trenk DiPasquale of West Orange, N.J., as a “buyout”.

Roll Call has ranked Rep. Darrell Issa, R-Calif., as the richest member of Congress with a reported minimum net worth of more than $355 million. Issa has surpassed Rep. Michael McCaul, R-Texas, the richest member at the end of 2011. Issa’s assets increased in 2012 by at least $135 million, and he made $59.5 million in income from those assets. View Roll Call article.

To search detailed money-in-politics databases, visit Political MoneyLine.

Comment (1)

  1. Michael

    Sept. 6, 2013
    9:38 p.m.

    How exactly did Warner buy $1MM worth of Novus on July 18th when it was delisted last year? http://www.4-traders.com/news/Cayman-Islands-Stock-Exchange–CSX-CANCELS-Novus-Global-Special-Situations-Strategy-Limited–15246961/

    And must be nice for a public servant to have $500K to drop in seed money for Norwegian Crystals AS.

    Come on Roll Call, do some digging.

Sign In

Forgot password?

Or

Subscribe

Receive daily coverage of the people, politics and personality of Capitol Hill.

Subscription | Free Trial

Logging you in. One moment, please...